Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GNAI3 | P08754 | 6/20 | 0.53 |
| ▸ | GNAO1 | P09471 | 6/20 | 0.53 |
| ▸ | GNAI1 | P63096 | 6/20 | 0.53 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.38 |
| ▸ | PPARD | Q03181 | 1/20 | 0.37 |
| ▸ | HRH2 | P25021 | 2/20 | 0.34 |
| ▸ | HRH1 | P35367 | 2/20 | 0.34 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | HTR4 | Q13639 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31638212 | 0.95 | GNAI3 (0.50) | GNAI3GNAO1GNAI1SPHK1PPARD | |
| SCHEMBL31638118 | 0.89 | GNAI3 (0.45) | GNAI3GNAO1GNAI1SPHK1PPARD | |
| SCHEMBL31638412 | 0.79 | GNAI3 (0.40) | GNAI3GNAO1GNAI1SPHK1PPARD | |
| SCHEMBL29012621 | 0.79 | GNAI3 (0.49) | GNAI3GNAO1GNAI1SPHK1HRH2 | |
| SCHEMBL26176475 | 0.78 | CXCR4 (0.42) | GNAI3GNAO1GNAI1PPARDHRH2 | |
| SCHEMBL9003135 | 0.77 | PPARD (0.44) | PPARDHRH3TSHR | |
| Butane SCHEMBL4648880 | 0.77 | GNAI3 (0.58) | GNAI3GNAO1GNAI1SPHK1 | |
| SCHEMBL29012623 | 0.75 | GNAI3 (0.44) | GNAI3GNAO1GNAI1SPHK1HRH2 | |
| SCHEMBL6941794 | 0.74 | GNAI3 (0.62) | GNAI3GNAO1GNAI1SPHK1HRH2 | |
| SCHEMBL18985145 | 0.73 | CXCR4 (0.41) | GNAI3GNAO1GNAI1PPARDHRH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080269170-A1 | Novel 2,4-Dianilinopyrimidine Derivatives, the Preparation Thereof, Their Use as Medicaments, Pharmaceutical Compositions and, in Particular, as IKK Inhibitors | SANOFI-AVENTIS (FR) | 2008-10-30 | — | — | US | disclosed |
| EP-1904479-A2 | NOVEL 2,4-DIANILINOPYRIMIDINE DERIVATIVES, THE PREPARATION THEREOF, THEIR USE AS MEDICAMENTS, PHARMACEUTICAL COMPOSITIONS AND, IN PARTICULAR, AS IKK INHIBITORS | Sanofi-Aventis (FR) | 2008-04-02 | — | — | EP | disclosed |
| WO-2007006926-A2 | NOVEL 2,4-DIANILINOPYRIMIDINE DERIVATIVES, THE PREPARATION THEREOF, THEIR USE AS MEDICAMENTS, PHARMACEUTICAL COMPOSITIONS AND, IN PARTICULAR, AS IKK INHIBITORS | SANOFI-AVENTIS (FR) | 2007-01-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080269170-A1 | Novel 2,4-Dianilinopyrimidine Derivatives, the Preparation Thereof, Their Use as Medicaments, Pharmaceutical Compositions and, in Particular, as IKK Inhibitors | NFKBIA, IKBKB, IKBKE | GNAI3 917/4885GNAO1 3197/4885GNAI1 566/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.